Ibtrozi
Payments companies reported to CMS as associated with Ibtrozi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ibtrozi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ibtrozi
These are the largest totals companies reported as associated with Ibtrozi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $13,440.00 |
| Mark Socinski | Orlando, FL | Hematology & Oncology | $3,780.00 |
| Guang Liu | Chandler, AZ | Clinical Cytogenetics | $3,120.00 |
| Wade Iams | Nashville, TN | Hematology & Oncology | $2,520.00 |
| Sarah Gordon | Richmond, VA | Hematology & Oncology | $2,520.00 |
| Nagashree Seetharamu | New Hyde Park, NY | Internal Medicine | $2,520.00 |
| Rachel Sanborn | Portland, OR | Medical Oncology | $2,100.00 |
| Jamie Chaft | New York, NY | Medical Oncology | $2,100.00 |
| Luis Raez | Pembroke Pines, FL | Hematology & Oncology | $2,100.00 |
| Jorge Gomez | New York, NY | Medical Oncology | $1,762.50 |
Prescribed Ibtrozi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.